Navigation Links
Vermillion Enhances Management Team With A Key Addition
Date:9/26/2011

ortfolio Management (Corporate) from 2004 to 2005, and Director, Research and Development (GIBCO™) from 2002 to 2003.  Dr. Munroe was Director of Technology Commercialization with Corning (Microarray Technologies) from 2000 to 2002, and has 10 years of pharmaceutical discovery research experience at R.W. Johnson Pharmaceutical Research Institute (1990 to 1995) and Allelix Biopharmaceuticals (1996 to 2000). Additionally, he has seven granted U.S. patents, and has authored peer-reviewed publications on the molecular basis of cancer, gastrointestinal disorders, inflammation and other topics.  

"The commercialization success of OVA1 and the solid foundation on which our OVA2 and peripheral artery disease (PAD) programs are based have given us the opportunity to expand our management team to meet both the commercialization and development requirements in order to drive stockholder value. In particular, we will proactively seek development partnerships that can leverage the value inherent in our OVA2 and PAD programs. Dr. Munroe's extensive industry experience will be invaluable in these initiatives. At the same time, we will be able to continue to grow OVA1 both domestically and internationally," said Gail S. Page, Chair and Chief Executive Officer of Vermillion, Inc.  

"I am very excited to join the executive management team at Vermillion," said Dr. Munroe. "With the introduction of OVA1, the first FDA-approved multi-analyte index for ovarian cancer, Vermillion has established itself as a leader in translating proteomic biomarker research into everyday medical practice.  I look forward to helping Gail and the team launch an exciting pipeline of IVDMIA diagnostics which today includes VASCLIR for PAD and OVA2, a next generation test for asymptomatic high-risk monitoring of ovarian cancer."

About Vermillion:

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value dia
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillion Appoints Distribution Partner for OVA1® in Israel and the Palestine Territories
2. Vermillion Reports Financial Results for the First Quarter 2011
3. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
4. Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists
5. Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
6. Vermillion Announces $21.8 Million Public Offering
7. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
8. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
9. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
10. Vermillion Reports Financial Results for the Third Quarter 2010
11. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... et MADRID , June ... orale (extrait 10503) effectuée lors de la réunion ... PharmaMar communique que Janssen Research & ... de l,étude multicentrique de phase III SAR3007 qui ... progression (PFS) avec la trabectédine (YONDELIS ® ) ...
(Date:6/1/2015)... , June 2, 2015 Amgen ... with Roche on a Phase 1b study to ... Amgen,s investigational oncolytic immunotherapy, in combination with Roche,s ... in patients with triple-negative breast cancer and colorectal ... is an investigational oncolytic immunotherapy designed to selectively ...
(Date:6/1/2015)... June 1, 2015 Lee Tran ... the Snapchat and Yik Yak ... against one of the most promising biotechnology start-ups in ... Meyer and Jeffrey Sabados .  LTL represents ... a former colleague and fellow scientist at the Massachusetts ...
Breaking Medicine Technology:PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 2PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 3PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 5PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Lee Tran & Liang LLP Files Co-Founder Lawsuit against Leading Biotech Start-up Resilience 2
... , ... ... ... ...
... ... ... ... , ...
Cached Medicine Technology:Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 2Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 3Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 4Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 5Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 6Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 7Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 8Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 9Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 10Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 11Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 12Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 13Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 14Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 15Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 16Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 17Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 18Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 2Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 3Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 4Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 5
(Date:6/1/2015)... 2015 On May 14, 2015, the ... hosted the Cherry Creek Chamber of Commerce for the ... care centers typically do not offer primary care services ... Cherry Creek Urgent Care staff to schedule family care ... 5:30 to 7:30 p.m. the center hosted presidents, CEOs, ...
(Date:6/1/2015)... EBSCO Health , a leading provider of ... , a cross-platform evidence-based clinical decision support tool for ... the ideal blend of evidence and expertise to help ... Plus is a significant enhancement over other tools currently ... evidence-based content. DynaMed Plus content is supplemented with full ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 "This milestone ... who were not previously able to buy and sell ... on unsolicited orders and also make recommendations to clients ... investors an ability to trade shares of our Company,” ... compliance and information requirements of OTCQB provides our investors ...
(Date:6/1/2015)... Pittsburgh, PA (PRWEB) June 01, 2015 ... this new development in breast cancer prevention. , A ... Health suggests that postmenopausal women with ductal carcinoma in ... cancer treatment and prevention. , The study (NSABP B-35/NRG ... those who completed the standard five-year treatment with tamoxifen ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 For years, ... requesting celebrity features. Much like one would request a ... noses, eyes, cheeks, chin and more to illustrate their ... apps like FaceTune are ushering in a new era ... facial plastic surgeon, Sam Rizk, MD, FACS notes that ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2
... 27 MediSend International has joined The Clinton ... to Action , a unique feature of CGI ... measurable results. Through its Afghanistan Health and Human ... training, comprehensive repair and maintenance kits, technical support ...
... fibrillation, other arrhythmias , MONDAY, Oct. 26 (HealthDay ... hard evidence that the characteristic snorting and gasping ... abnormalities. , Previous studies have suggested an association ... had not established a cause-and-effect relationship, said study ...
... with pleasure that the Spain-United States Chamber of Commerce ... which is slated to increase attendance in 2009, will be held ... Nov. 6th. The gala recognizes Spain-native, U.S.-based companies and ... This year, The Chamber will honor IBT GROUP ...
... of severe physical, psychosocial suffering, researchers say , MONDAY, ... World War II, those who were potentially exposed to ... due to physical and mental stress, an Israeli study ... rates in more than 300,000 Israeli Jews who were ...
... that a sometimes deadly stomach bug, Clostridium difficile ... Clostridium difficile is a serious bacteria that ... of the colon. These findings were presented today at ... in San Diego. Clostridium difficile , often ...
... BOSTON, Oct. 26 Uno Chicago Grill®, America,s Healthiest Chain ... limited-time-only fall menu. , This exciting fall menu ... cranberries are a well-known and popular accent to many dishes, ... once the territory of a select few health food aficionados. ...
Cached Medicine News:Health News:MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative 2Health News:MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative 3Health News:Sleep Apnea Episodes May Trigger Irregular Heartbeat 2Health News:Spain-United States Chamber of Commerce Announces 30th Annual Gala Honoring IBT Group at The Biltmore Hotel - November 6 2Health News:Exposure to Holocaust May Have Raised Cancer Risks 2Health News:Deadly stomach infection rising in community settings, Mayo Clinic study finds 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 3
Refrigerator specially designed for the storage of blood in standard 500ml bags, complying with Australian Standard AS3864 1997....
TBR-120-1-GD is large capacity upright style refrigerator with an operating temperature of +4C. It is a specially designed refrigerator for the storage of blood in standard 500ml bags, complying with...
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
... is a direct competitive EIA for ... human serum or plasma. A specific ... making it available for antibody binding. ... antibody linked to fluorescein isothiocyanate (FITC) ...
Medicine Products: